Targeting of protein translation as a new treatment paradigm for prostate cancer.

**Title**
Targeting of protein translation as a new treatment paradigm for prostate cancer.

**Publication Type**
Journal Article

**Year of Publication**
2017

**Authors**
Ramamurthy, VP, Ramalingam, S, Kwegyir-Afful, AK, Hussain, A, Njar, VCO

**Journal**
Curr Opin Oncol

**Date Published**
2017 Mar 09

**ISSN**
1531-703X

**Abstract**

**PURPOSE OF REVIEW:** The current overview will summarize some of the developments in the area of protein translation, including their relation to the therapeutic targeting of prostate cancer.

**RECENT FINDINGS:** Translational control, mediated by the rate-limiting eukaryotic translation initiation factor 4E (eIF4E), drives the proliferation of prostate cancer cells. Research in this area has identified several novel targets and therapeutic strategies that are being actively studied, and it is likely that some may ultimately emerge as promising anticancer therapeutics.

**SUMMARY:** An array of inhibitors has shown promise in targeting specific components of the translational machinery in several prostate cancer cell lines. Current efforts are focused on developing more effective and selective inhibitors that could ultimately have relevance in improving the clinical outcomes of patients with advanced prostate cancer.

**DOI**
10.1097/CCO.0000000000000367

**Alternate Journal**
Curr Opin Oncol

**PubMed ID**
28282343